Clinical trial recruitment for ABBV-744 study Fundamentals Explained
In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, contributors will obtain ABBV-744 and ruxolitinib. Members will receive treatment till illness progression or maybe the participants are not able to tolerate the study drugs.There may be higher treatment load for members On this trial in comparison to their standard